Skip to main content
Premium Trial:

Request an Annual Quote

Syapse, Non-Profit Health Systems Form Cancer Data-Sharing Consortium

NEW YORK (GenomeWeb) – Syapse, Intermountain Healthcare, Stanford Cancer Institute, and Providence Health & Services announced today that they have established a consortium to advance cancer precision medicine by accelerating data sharing between clinics and health systems. 

Called the Oncology Precision Network (OPN), the initiative aims to link and share aggregated clinical, molecular, and treatment data between its members using Syapse technology, enabling cancer patients not treated by major cancer centers to benefit from high volume-based analytics.

The OPN database is expected to launch with 100,000 datasets and grow as other health systems sign on. When fully implemented, the OPN anticipates impacting 50,000 new cancer patients and 200,000 total cancer patients annually, and have data available on more than 1.5 million historical cancer cases.

"This consortium exists because we all arrived at the same important conclusion: we need to collaborate across health systems to cure cancer," Lincoln Nadauld, executive director of Intermountain Precision Genomics, said in a statement. "Through collaboration, we emphasize the need to learn together to empower physicians and patients in finding solutions to cancer without increasing costs."

"This dynamic network will also allow us to approach precision oncology from a big data point of view," Jim Ford, director of clinical cancer genomics at the Stanford Cancer Institute, added. "By aggregating all of our real patient experiences, we will rapidly expand our ability to learn how to choose the best targeted treatments for our cancer patients based on the molecular profile of their tumor and our informatics based research."

Formation of the OPN comes just a few months after Syapse created its Global Partner Program to boost adoption of its Precision Medicine Platform, which pools cancer information from genomic testing and analysis, personalized treatment regimens, and clinical and outcomes data.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.